发明公开
EP2364728A1 Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
审中-公开
Menschliche抗NGF-neutralisierendeAntikörperALS selektive NGF-Pfadhemmer
- 专利标题： Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
- 专利标题（中）： Menschliche抗NGF-neutralisierendeAntikörperALS selektive NGF-Pfadhemmer
-
申请号： EP10011652.4申请日： 2004-07-15
-
公开(公告)号： EP2364728A1公开(公告)日： 2011-09-14
- 发明人: Wild, Kenneth D., Jr. , Treanor, James J.,S. , Huang, Haichun , Inoue, Heather , Zhang, Tie, J. , Martin, Frank
- 申请人： Amgen, Inc , Medarex, Inc.
- 申请人地址： One Amgen Center Drive Thousand Oaks, CA 91320-1799 US
- 专利权人： Amgen, Inc,Medarex, Inc.
- 当前专利权人： Amgen, Inc,Medarex, Inc.
- 当前专利权人地址： One Amgen Center Drive Thousand Oaks, CA 91320-1799 US
- 代理机构： Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät
- 优先权： US487431P 20030715
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; C07K16/22 ; G01N33/53 ; C12N15/68 ; C12N5/10 ; A61P25/00 ; A61P35/00
摘要：
This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
信息查询
